MedPath

Nasal Decongestion and Obstructive Sleep Apnea

Phase 4
Completed
Conditions
Obstructive Sleep Apnea Syndrome
Rhinitis
Interventions
Registration Number
NCT00630474
Lead Sponsor
University of Zurich
Brief Summary

Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
12
Inclusion Criteria
  • Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index >10/h)
  • Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months)
Exclusion Criteria
  • Nasal surgery within the last 6 months
  • Current treatment with nasal decongestants or topical steroids
  • Sleep disorders other than obstructive sleep apnea
  • Internal medical or psychiatric disorders that interfered with sleep

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
1xylometazolinenasal application of xylometazoline
2xylometazolinenasal application of placebo
Primary Outcome Measures
NameTimeMethod
sleep related breathing disturbances sleep efficiency daytime sleepinessat end of one week treatment
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Pulmonary Division, University Hospital Zurich

🇨🇭

Zurich, Switzerland

Pulmonary Division, University Hospital Zurich, Switzerland

🇨🇭

Zurich, Switzerland

© Copyright 2025. All Rights Reserved by MedPath